1. Home
  2. BILL vs ACAD Comparison

BILL vs ACAD Comparison

Compare BILL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$34.15

Market Cap

3.3B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.23

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
ACAD
Founded
2006
1993
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.8B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
BILL
ACAD
Price
$34.15
$21.23
Analyst Decision
Buy
Buy
Analyst Count
21
22
Target Price
$57.90
$30.55
AVG Volume (30 Days)
2.9M
1.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
74.07
69.12
EPS
0.07
0.02
Revenue
$1,462,570,000.00
$726,437,000.00
Revenue This Year
$14.18
$18.80
Revenue Next Year
$13.83
$11.70
P/E Ratio
$474.00
$1,054.50
Revenue Growth
13.36
40.45
52 Week Low
$31.52
$19.69
52 Week High
$57.21
$28.35

Technical Indicators

Market Signals
Indicator
BILL
ACAD
Relative Strength Index (RSI) 43.19 46.67
Support Level N/A $21.04
Resistance Level $40.50 $22.03
Average True Range (ATR) 1.82 0.58
MACD -0.28 0.00
Stochastic Oscillator 31.60 34.91

Price Performance

Historical Comparison
BILL
ACAD

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: